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Abstract The study aimed to examine the effect of gastric
bypass on diabetic nephropathy (DN) in Chinese patients. A
retrospective study of 101 samples with DN stages I to IV
underwent Roux-en-Y gastric bypass. Anthropometric and
biochemical parameters were assessed during a 1-year fol-
low-up. Binary logistic regression analysis was used for pre-
dictors and ROC for cutoff points. There was significant re-
duction of medication for diabetes and hypertension. Overall
remission of T2DM was 80.2 %. Preoperative albumin/
creatinine ratio (ACR) and serum creatinine (SCr) levels could
be predictors for DN remission, and the cutoff points were
126 mg/g cr and 57 μmol/L, respectively. Gastric bypass
showed improvement of T2DM and DN. Gastric bypass
may be more beneficial for those with lower preoperative
ACR and SCr.
Keywords Gastricbypass .Type2diabetesmellitus .Diabetic
nephropathy .Microalbuminuria . Albumin/creatinine ratio
The incidence of diabetes mellitus has risen rapidly in the past
few decades, and its prevalence has increased from less than
1% in the Chinese population in the 1980s [1] to 11.6 % in the
Chinese adult population [2]. Even more serious is that only
25.8 % of these patients received treatment for diabetes, and
only 39.7 % of those treated had adequate glycemic control.
These findings indicate the importance of diabetes as a public
health problem in China with the potential for a major epi-
demic of diabetes-related complications.
Diabetic nephropathy (DN), also known as diabetic
glomerulosclerosis or diabetic kidney disease, is one of
the major microvascular complications of type 2 diabe-
tes mellitus (T2DM) [2–4], and is a leading cause of
end-stage renal disease (ESRD) with high mortality [5,
6]. Current strategies for the treatment of DN to delay
progression involve control of blood glucose and meta-
bolic abnormality [7].
Metabolic surgery has been approved as an effective
and potentially useful treatment for T2DM with obesity,
especially the Roux-en-Y gastric bypass (RYGB)
[8–10]. Several observational studies have shown im-
pressive improvements in glycemic as well as in meta-
bolic disorder, and diabetic complications have shown
to be partially reversible due to weight loss and diabetes
control [11, 12]. Our prior studies have also shown
significant improvement in T2DM including erectile
dysfunction and obstructive sleep apnea [13–15].
Though the evidence suggests that RYGB might be a po-
tential treatment for DN, it remains unclear whether the sur-
gery improves progression or provides remission for incipient
and overt nephropathy. Therefore, the aim of our study was to
investigate whether the RYGB is appropriate for DN.
Methods
A retrospective study was made between February 2011 and
December 2013. A total of 157 patients had RYGB during this
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period, and 101 T2DM patients with different DN stages were
enrolled. The inclusion criteria included (1) age from 18 to
65 years, (2) BMI over 28 kg/m2, (3) a diagnosis of T2DM
based on the criteria of the American Diabetes Association
(ADA), and (4) a fasting C-peptide by the oral glucose toler-
ance test >1 ng/mL and a ratio of peak to fasting value >2 ng/
mL. Those with established diagnoses of type 1 diabetes, la-
tent autoimmune diabetes in adults, malignancy, debilitating
disease, unresolved psychiatric illness, or substance abuse
were excluded from the study.
DN is divided into five stages according to the Morgenson
standard [16]: (I) hyperfunction with raised glomerular filtra-
tion rate (GFR) and increased kidney volume, (II)
normoalbuminuria with the thickening of the glomerular base-
ment membrane (GBM) and expansion of the mesangial ma-
trix, (III) incipient DN with microalbuminuria (MAU) 30–
299 mg/day, (IV) overt DN with MAU >300 mg/day, and
(V) uremia with ESRD. Patients with DN stage V were ex-
cluded from this study for surgical contraindication. Remis-
sion in DN stages III and IV was defined as MAU <30 mg/
day. This study focused on patients in DN stage III and IV,
which are more likely to develop end-stage renal disease.
Medical history, current medications, anthropometric eval-
uations including weight, BMI, percent of excess weight loss
(%EWL), waistline, and hipline were recorded before and
after bypass surgery. Biochemical parameters were evaluated
by obtaining blood samples after an overnight fast and includ-
ed fasting glucose, postprandial glucose followed by OGTT,
fasting C-peptide, glycated hemoglobin (HbA1c), glycosylat-
ed serum protein (GSP), lipid profile (cholesterol, triglyceride,
high-density, and low-density lipoprotein), and renal function
profile (blood urea nitrogen [BUN], serum creatinine [SCr],
and uric acid [UA]). In addition, the screening of DN with
GFR, urine albumin/creatinine ratio (ACR), and 24-h
microalbuminuria were evaluated. Insulin resistance level
and β-cell function were measured by the homeostasis model
assessment insulin resistance (HOMA-IR) using the formula
mIU/mmol/L2=fasting insulin (mIU/L)×fasting glucose
(mmol/L)/22.5 and the homeostasis model assessment β-
cell (HOMA-β) using%=20×fasting insulin (mIU/L)/fasting
glucose (mmol/L)−3.5) (%).
Remission of T2DM was defined as an HbA1c level
<6.5 % and a fasting glucose concentration <7.0 mmol/L for
1 year or more without active pharmacologic intervention
[17]. Plasma glucose concentrations were measured using
the glucose oxidase method. Serum insulin and C-peptide
levels were quantified using radioimmunoassays with specific
insulin and C-peptide detection kits according to the manufac-
turer’s instructions (Beijing North Institute of Biological
Technology, Beijing, China). HbA1c was measured by HPLC
(Menarini, former reference range 4.0–6.0 %). GSP was mea-
sured by ELISA (Hitachi 7100, Tokyo, Japan). The serum
lipid and renal function profile were measured using standard
commercial methods on a parallel, multichannel analyzer
(Hitachi 7600–020, Tokyo, Japan). ACR and 24-hMAUwere
measured by chemiluminescence immunoassay (Siemens,
DCA Vantage, Germany), and GFR was measured by 99 m
Tc-DTPA (Siemens, SPECT, E CAM Single, Germany).
Of the 101 patients, 45 (44.6 %) were female. The mean
age of all participants was 47.6±11.9 years, and the mean
duration of T2DM was 7.63±4.84 years. Hypertension was
diagnosed in 40 (39.6 %). All patients were divided into four
groups according to their DN stage diagnosis.
Nearly 50 % were treated with insulin and more than 60 %
with oral diabetes medications in each group preoperatively.
Patients in DN stage I with hypertension (25.8%) had the least
proportion of antihypertensives (12.9 %). Most of the antihy-
pertensives taken were angiotensin-converting enzyme
Table 1 Characteristics of the
participants DN1 DN2 DN3 DN4
Gender (F/M) 16:15 08:26 11:10 10:05
Age (years) 41.35±9.37 54.91±10.23 47.62±13.70 44.13±8.70
Duration (years) 4.87±2.85 9.94±4.57 7.18±5.60 8.33±4.92
Hypertension 8 (25.8 %) 14 (41.2 %) 11 (52.4 %) 7 (46.7 %)
Medication use before surgery
Insulin 10 (47.6 %) 17 (50.0 %) 9 (42.9 %) 13 (46.7 %)
Oral diabetes medications 19 (61.3 %) 25 (73.5 %) 13 (61.9 %) 9 (60.0 %)
Antihypertensives 4 (12.9 %) 12 (35.3 %) 9 (42.9 %) 6 (40.0 %)
Antihyperlipidemia 15 (48.4 %) 12 (35.3 %) 13 (61.9 %) 8 (53.3 %)
Medication use 1 year after surgery
Insulin 1 (3.2 %) 2 (5.9 %) 1 (4.8 %) 1 (6.7 %)
Oral diabetes medications 2 (6.5 %) 2 (5.9 %) 2 (9.5 %) 1 (6.7 %)
Antihypertensives 2 (6.5 %) 5 (14.7 %) 2 (9.5 %) 1 (6.7 %)
Antihyperlipidemia 1 (3.2 %) 1 (2.9 %) 1 (4.8 %) 0
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inhibitor (ACEI) or/with angiotensin receptor blocker (ARB).
Antihyperlipidemia medication was taken by 61.9 and 60 %
separately in DN stages III and IV while in DN stages I and II,
it was 48.4 and 35.3 %, respectively (Table 1).
Surgical Technique
All patients had laparoscopic Roux-en-Y gastric bypass
(LRYGB) by the same surgical team with over 50 cases of
experience. The patient was placed in reverse Trendelenburg
position and the surgeon positioned between the patient’s legs.
Five trocars are inserted under direct laparoscopic vision. A
gastric pouch of approximately 30mL is created with mechan-
ical sutures preventing the transection of the left gastric artery.
The angle of Treitz is then identified, and a 100-cm-long je-
junal loop (biliopancreatic limb) is ascended anterior to the
colon and anastomosed to the gastric pouch with mechanical
linear suture (30 mm). A lateral jejuno-jejunal anastomosis
adjacent to gastro-jejunal anastomosis is made 100 cm away
from the previous nastomosis (alimentary limb) with a me-
chanical linear stapler.
Statistics Analysis
All statistics were calculated with SPSS statistical software
(version 20.0; SPSS Inc., Armonk, NY, USA). Paired t tests
were used to compare variables before and after the study.
Contingency tables of categorical variables were analyzed
by Fisher’s exact test (grade and gender in remission of DN
stages III and IV). Correlations between clinical parameters
and MAU were analyzed by partial correlation analysis. Mul-
tiple stepwise logistic regression analysis was performed to
assess the independent predictive effects of the variables on
remission of DN. The measure index was set as blood pres-
sure, albumin/creatinine ratio and serum creatinine, and the
remission standard as MAU <30 mg/day. The predictors’ cut-
off point was evaluated by Youden’s Index with the receiver
operating characteristic (ROC) curve. Data are presented as
the mean±SD. Statistical significance was defined as P<0.05.
Results
Four groups are comparable in BMI (F=1.529, P=0.212),
patients in DN stage II were older (F=0.915, P=0.000) and
longer T2DM duration (F=6.975, P=0.000). One year after
surgery, there was a significant reduction of each type of med-
ication used in each group (Table 1).
The overall remission of T2DM was 80.20 %, and in DN
stage I, it was 95.2 %, DN stage II was 86.7 %, DN stage III
was 23.8 %, and DN stage IV was 46.7 %. Changes in anthro-
pometric and biochemical parameters of all patients before
and after surgery are shown in Table 2.
The overall remission of DN stages III and IV was 58.3 %.
There was no significant difference in age or BMI between
two groups. Analysis showed that the remission parameter
microalbuminuria was correlated with albumin/creatinine ra-
tio, systolic blood pressure (SBP), serum creatinine, Homa-
IR, Homa-β, fasting C-peptide, and cholesterol levels
(Table 3). According to the DN remission standard for incip-
ient (stage III) and overt (stage IV) nephropathy, the preoper-
ative clinical variables related to diabetes were assessed for
their predictive values (Table 4). Analysis showed that in DN
patients with stage III, there were lower microalbuminuria,
albumin/creatinine ratio, systolic blood pressure, blood urea
nitrogen, and serum creatinine levels compared with those
without remission. Preoperative BMI, diabetes duration,
waistline, and GFR had no significant differences between
the two groups. The results of multivariate regression analysis
confirmed that systolic blood pressure, serum creatinine and
albumin/creatinine ratio were clinical predictors for DN remis-
sion (Table 5). Further analysis for predicting the DN remis-
sion using ROC showed that AUC in serum creatinine and
albumin/creatinine ratio was 0.770 and 0.917 with the cutoff
point of 57 μmol/L in serum creatinine and 126 (mg/g cr) in
albumin/creatinine ratio (Table 6).
Discussion
Recently, there have been many encouraging reports suggest-
ing that gastric bypass is an effective, stand-alone procedure
for T2DM with obesity. However, before discussing DN re-
mission, the primary concern should be about safety. In our
study, all surgeries were performed by one team with experi-
ence of over 50 cases of LRYGB. An important aspect in the
learning curve for successful metabolic surgery, according to
Huang [18], is having experience of approximately 30 cases.
Common complications such as fistula, obstruction, stenosis,
and hemorrhage did not occur in our study. In addition, there
was no acute renal failure in the patients with DN stage III or
IV.
The primary aim of DN treatment is currently focused on
delaying its progression by improving the control of T2DM
and of hemodynamic abnormalities [8]. Evidence shows that
DN is characterized by structural and functional changes,
which show an imbalance in afferent and efferent arteriolar
resistance and may result in increased glomerular hydrostatic
pressure and hyperfiltration [19, 20].
The present study advocates that vascular endothelial dys-
function leads to changes in the renal vascular system and
contributes to the development of DN. Good glycemic control
is effective in reducing diabetic microvascular complication
[21]. Hemodynamic dysfunction could be another factor
resulting in DN, and diabetic endothelial nitric oxide synthase
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knockout mice develop more severe glomerular lesions and
proteinuria compared to wild-type mice [22].
A recently described mechanism of proximal tubule injury
that involved the formation of advanced glycation end-
products (AGE) by nonenzymatic binding of glucose to pro-
teins, lipids, and nucleic acids can lead to alteration of protein
structure and function, oxidative stress, and expression of pro-
inflammatory cytokines and growth factors [23], which cause
the development of DN [24]. In addition, evidence suggests
that genetic predisposition, hyperglycemia, hypertension, and
dyslipidemia, all factors associated to metabolic syndrome,
contribute to the induction and progression of DN [25]. Thus,
controlling and improving metabolic syndrome could be the
key link to DN treatment. However, current strategies includ-
ing diabetic medicines, antihypertensives, and antilipid medi-
cine are not effective.
This study confirms the remarkable efficacy of gastric by-
pass for treatment of T2DM with obesity. The percentage of
female patients participating was 44.6 %, which is lower than
in other studies. The overall remission of T2DM after 1 year
was 80.20 %. The central obesity status, hypertension, and
Table 4 Comparison of preoperative factors of DN remission in grade
III and IV
Factor Remission No remission P value
DN grade (III/IV) 19:2 2:13 0.000**
Gender (F/M) 11:10 4:11 0.123
Age (years) 46.48±13.60 45.73±9.31 0.856
Duration (years) 6.85±5.58 8.80±4.78 0.280
Weight (kg) 88.79±11.72 90.37±13.09 0.706
BMI (kg/m2) 31.94±3.86 31.44±3.17 0.682
Waistline (cm) 106.14±9.96 104.53±8.69 0.618
Hipline (cm) 109.05±7.43 107.00±6.29 0.392
MAU (mg/24 h) 132.32±201.92 984.30±995.50 0.005**
GFR (mL/min) 109.89±24.56 92.78±28.73 0.067
ACR (mg/g cr) 120.37±169.61 650.48±820.04 0.026*
HR (bpm) 77.00±6.62 79.27±3.41 0.234
SBP (mmHg) 129.28±15.35 138±9.82 0.049*
DBP (mmHg) 122.14±160.91 81.20±7.06 0.334
BUN (mmol/L) 4.72±1.45 5.87±1.96 0.049*
SCr (μmol/L) 57.62±16.11 80.93±28.61 0.010**
UA (μmol/L) 372.00±110.74 389.40±131.00 0.669
FBG (mmol/L) 8.67±1.67 8.27±2.70 0.585
PBG (mmol/L) 13.78±3.46 13.00±5.11 0.586
CP 0 (ng/mL) 2.73±1.25 3.04±1.86 0.550
HbA1c (%) 8.27±1.83 8.05±1.79 0.722
GSP (%) 19.45±4.86 17.97±4.00 0.353
HOMA-IR 8.81±7.30 24.76±45.92 0.125
HOMA-β (%) 105.93±108.72 1042.83±3335.05 0.204
CH (mmol/L) 5.11±1.13 4.90±0.99 0.574
TG (mmol/L) 2.85±2.28 2.71±1.36 0.842
HDL (mmol/L) 1.02±0.23 0.95±0.20 0.339
LDL (mmol/L) 2.85±0.92 2.82±0.85 0.923
BMI body mass index, MAU microalbuminuria, GFR glomerular filtra-
tion rate, ACR albumin/creatinine ratio,HR heart rate, SBP systolic blood
pressure, DBP diastolic blood pressure, BUN blood urea nitrogen, SCr
serum creatinine, UA uric acid, FPG fasting plasma glucose, PBG post-
prandial glucose, HbA1c hemoglobin A1c, GSP glycosylated serum pro-
tein, CP 0 fasting C-peptide, HOMA-IR homeostasis model assessment-
insulin resistance, HOMA-β homeostasis model assessment β-cell, TG
triglycerides, CH cholesterol, HDL high-density lipoprotein, LDL low-
density lipoprotein
Data represent means±SD or median (interquartile range) or percentages
*P<0.05; **P<0.01
Table 3 The correlation test for MAU in patients with DN III/IV
MAU
r P
Age (years) −0.063 0.543
Duration (years) 0.099 0.346
GFR (mL/min) −0.161 0.062
ACR (mg/g cr) 0.962 0.000**
Weight (kg) 0.040 0.479
BMI (kg/m2) 0.105 0.065
%EWL −0.003 0.961
Waistline (cm) 0.041 0.474
Hipline (cm) 0.015 0.794
HR (bpm) 0.069 0.229
SBP (mmHg) 0.126 0.026*
DBP (mmHg) −0.005 0.936
BUN (mmol/L) 0.110 0.053
SCr (μmol/L) 0.256 0.000**
UA (μmol/L) 0.067 0.242
FBG (mmol/L) 0.072 0.207
PBG (mmol/L) 0.058 0.310
HbA1c (%) 0.049 0.310
GSP (%) −0.069 0.226
HOMA-IR 0.336 0.000**
HOMA-β (%) 0.264 0.000**
CP 0 (ng/mL) 0.112 0.049*
CH (mmol/L) 0.173 0.002**
TG (mmol/L) 0.051 0.370
HDL (mmol/L) 0.083 0.143
LDL (mmol/L) 0.083 0.143
BMI body mass index, %EWL percentage of excess weight loss, MAU
microalbuminuria, GFR glomerular filtration rate, ACR albumin/creati-
nine ratio, HR heart rate, SBP systolic blood pressure, DBP diastolic
blood pressure, BUN blood urea nitrogen, SCr serum creatinine, UA uric
acid, FPG fasting plasma glucose, PBG postprandial glucose, HbA1c
hemoglobin A1c, GSP glycosylated serum protein, CP 0 fasting C-pep-
tide, HOMA-IR homeostasis model assessment-insulin resistance,
HOMA-β homeostasis model assessment β-cell, TG triglycerides, CH
cholesterol, HDL high-density lipoprotein, LDL low-density lipoprotein
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lipid levels were significantly improved in all DN groups.
Further analysis showed that patients in DN stage I were
younger with shorter diabetes duration, less insulin resistance,
and better blood pressure control compared with those in DN
stages III and IV before surgery. Despite the differences in the
four groups, the 1-year follow-up showed that gastric bypass
can also lead to similar recovery of metabolic disorder. Al-
though HOMA-IR and HOMA-β in DN stage IV showed
impressive improvement, they were significantly higher than
in the other three groups 1 year following surgery, which
represents greater insulin resistance and poor β-cell function
indicating progression of DN. Furthermore, the medication
used for diabetes, hypertension, and hyperlipidemia was re-
duced significantly in all groups after surgery.
Most patients with hypertension in our study used ACEI
and/or ARB, which could reduce the risk of albuminuria to
control blood pressure [26]. After surgery, antihypertensive
medication was significantly reduced and most patients be-
came well controlled with blood pressure under 130/
80 mmHg. A study by Pohl et al. [27] indicated that a target
systolic blood pressure of 120–130 mmHg provided tremen-
dous benefit to renal outcomes. Our study found that patients
in DN stages I to IV maintained continuous improvement for
metabolic disorder in 1-year short term. In addition, weight
loss and better diabetic control improved the lifestyle of pa-
tients and also provided further benefit by slowing down the
progression of DN.
The renal function index including serum creatinine, blood
urea nitrogen, uric acid, and GFR had no significant changes.
However, microalbuminuria and albumin/creatinine ratio
were significantly reduced in DN stages I, II, and III, but not
in patients in stage IV. The mean level reduced continuously.
The microalbuminuria reflects the glomerular filtration func-
tion due to the change in endothelial cell permeability and
glomerular basement membrane. The GFR is affected by sev-
eral factors including the glomerular filtration function, glo-
merular hydrostatic pressure, and colloid osmotic pressure.
Therefore, we speculate that gastric bypass could improve
the capillary membrane permeability, but the complex connec-
tion between capillary hemodynamics and gastric bypass still
needs further research.
Patients with DN at the time of T2DM diagnosis can go
unrecognized for years. Albuminuria is common among pa-
tients with established diabetes, and becomes more prevalent
with worsening glucose tolerance [28]. DN stages III and IV,
which are also called incipient and overt nephropathy, are
more likely to develop end-stage renal disease [29]. Therefore,
our study has focused on the change of microalbuminuria
especially in DN stages III and IV following surgery. The
remission of DN (decrease in MAU to <30 mg/24 h) could
slow the progression of nephropathy and may prevent the
development of end-stage renal disease. As for patients in
stages I and II, DN were controlled by reducing of GFR and
microalbuminuria 1 year after surgery.
Our study found that patients in DN stage III are more
likely to get remission compared with stage IV, but gender,
age, and diabetic duration were not correlated. The renal func-
tion index including microalbuminuria, albumin/creatinine ra-
tio, serum creatinine, and blood urea nitrogen had a significant
difference in both patients with and without remission before
surgery. Further analysis shows significant correlation with
albumin/creatinine ratio, serum creatinine, systolic blood pres-
sure, cholesterol and insulin sensitivity, and insulin resistance.
This result confirms the relationship between DN and meta-
bolic disorder.
In our study, patients with increased baseline of systolic
blood pressure, serum creatinine, or albumin/creatinine ratio
are less likely to achieve remission of DN, and the ROC curve
revealed that serum creatinine and albumin/creatinine ratio are
potential predicators for remission failure of incipient and
overt DN. Youden’s Index showed that the cutoff point for
serum creatinine and albumin/creatinine ratio were 57 μmol/
L and 126 mg/g cr, respectively. As a normal value of the
serum creatinine cutoff point with less applicability, the
albumin/creatinine ratio cutoff point may have greater clinical
value. Although most patients in stage IV did not reach the
remission standard, the reduction of microalbuminuria helped
to stabilize DN.
Our study has several limitations such as retrospective de-
sign, small population size, and the limited follow-up duration
which may have interfered with the results. The study by
Alexander et al. showed that loss of excess body weight had
Table 6 ROC for remission of DN in predictors
AUC p valve 95 % CI Cutoff point
SBP 0.4 0.312 0.212 0.588 –
SCr 0.77 0.006 0.616 0.923 57
ACR 0.917 0.000 0.826 1.000 126
SBP had no predictive value (AUC<0.5). For SCr (AUC=0.77) and
ACR (AUC=0.917), ACR had best predictive value and accuracy for
predict DN remission, AUC >0.9
SBP systolic blood pressure, SCr serum creatinine, ACR albumin/creati-
nine ratio, AUC area under curve
Table 5 Multiple logistic regression analysis of variables at baseline
B SE P value Exp(B)
SBP −0.208 0.087 0.017 0.812
SCr 0.093 0.044 0.034 1.098
ACR 0.005 0.002 0.019 1.005
Predicted Probability is of membership for none remission
B coefficient of regression, SE standard error, Exp(B) odd ration, SBP
systolic blood pressure, SCr serum creatinine, ACR albumin/creatinine
ratio
1268 OBES SURG (2015) 25:1263–1270
the most positive effect in patients with obesity-related focal
segmental glomerulosclerosis [30], which differs from our
study. Therefore, a study with a long-term follow-up and a
large population sample is necessary to strengthen and estab-
lish the cutoff values for serum creatinine and albumin/
creatinine ratio. In addition, a further study with prospective
design is required to confirm whether DN remission after
RYGB is a temporary result or has a long-term effect. It is
also necessary to perform a pathology and pathophysiology
study of DN before and after surgery.
In conclusion, the beneficial results observed in our study
demonstrate that gastric bypass should be considered in Chi-
nese patients with T2DM and obesity. The RYGB shows the
possibility of slowing down progression of diabetic nephrop-
athy. Furthermore, albumin/creatinine ratio could help predict
the remission of DN.
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